-
1
-
-
0037125379
-
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial
-
Rossouw JE, Anderson GL, Prentice RL, Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-333
-
(2002)
JAMA
, vol.288
, pp. 321-333
-
-
Rossouw, J.E.1
Anderson, G.L.2
Prentice, R.L.3
-
2
-
-
0032547326
-
Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group
-
Hulley S, Grady D, Bush T, Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280: 605-613
-
(1998)
JAMA
, vol.280
, pp. 605-613
-
-
Hulley, S.1
Grady, D.2
Bush, T.3
-
3
-
-
0025940856
-
Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the Nurses' Health Study
-
Stampfer MJ, Colditz GA, Willett WC, Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the Nurses' Health Study. N Engl J Med 1991; 325: 756-762
-
(1991)
N Engl J Med
, vol.325
, pp. 756-762
-
-
Stampfer, M.J.1
Colditz, G.A.2
Willett, W.C.3
-
4
-
-
0033542402
-
The protective effects of estrogen on the cardiovascular system
-
Mendelsohn ME, Karas RH,. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999; 340: 1801-1811
-
(1999)
N Engl J Med
, vol.340
, pp. 1801-1811
-
-
Mendelsohn, M.E.1
Karas, R.H.2
-
5
-
-
33645763750
-
-
European Agency for the Evaluation of Medicinal Products (EMEA. Available at. Accessed May 15, 2014
-
European Agency for the Evaluation of Medicinal Products (EMEA). EMEA public statement on recent publications regarding hormone replacement therapy. Available at: http://www.cbg meb.nl/NR/rdonlyres/7152423E-6A92-4018-89B2.F9EBA8B26CA8/0/20031203pbhrtemeadec03.pdf. Accessed May 15, 2014
-
EMEA Public Statement on Recent Publications Regarding Hormone Replacement Therapy
-
-
-
6
-
-
0037505781
-
The estrogen and progestin dilemma: New advice, labeling guidelines
-
Bren L,. The estrogen and progestin dilemma: new advice, labeling guidelines. FDA Consum 2003; 37: 10-11
-
(2003)
FDA Consum
, vol.37
, pp. 10-11
-
-
Bren, L.1
-
7
-
-
51949110031
-
Health related quality of life after combined hormone replacement therapy: Randomised controlled trial
-
Welton AJ, Vickers MR, Kim J, Health related quality of life after combined hormone replacement therapy: randomised controlled trial. BMJ 2008; 337: a1190
-
(2008)
BMJ
, vol.337
, pp. a1190
-
-
Welton, A.J.1
Vickers, M.R.2
Kim, J.3
-
8
-
-
0028284928
-
Quality of life after the menopause: Influence of hormonal replacement therapy
-
Limouzin-Lamothe MA, Mairon N, Joyce CR, Le Gal M,. Quality of life after the menopause: influence of hormonal replacement therapy. Am J Obstet Gynecol 1994; 170: 618-624
-
(1994)
Am J Obstet Gynecol
, vol.170
, pp. 618-624
-
-
Limouzin-Lamothe, M.A.1
Mairon, N.2
Joyce, C.R.3
Le Gal, M.4
-
9
-
-
84873410348
-
Initiating therapy with antidepressants after discontinuation of hormone therapy
-
Citarella A, Andersen M, Sundstrom A, Bardage C, Hultman CM, Kieler H,. Initiating therapy with antidepressants after discontinuation of hormone therapy. Menopause 2013; 20: 146-151
-
(2013)
Menopause
, vol.20
, pp. 146-151
-
-
Citarella, A.1
Andersen, M.2
Sundstrom, A.3
Bardage, C.4
Hultman, C.M.5
Kieler, H.6
-
10
-
-
76649124594
-
-
Available at Accessed May 15, 2014
-
National Board of Health. Available at: http://www.socialstyrelsen.se/statistik/statistikdatabas/lakemedel Accessed May 15, 2014
-
National Board of Health
-
-
-
11
-
-
70449521194
-
The swedish personal identity number: Possibilities and pitfalls in healthcare and medical research
-
Ludvigsson JF, Otterblad-Olausson P, Pettersson BU, Ekbom A,. The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol 2009; 24: 659-667
-
(2009)
Eur J Epidemiol
, vol.24
, pp. 659-667
-
-
Ludvigsson, J.F.1
Otterblad-Olausson, P.2
Pettersson, B.U.3
Ekbom, A.4
-
12
-
-
79957607349
-
Estimates of statin discontinuation rates are influenced by exposure and outcome definitions
-
Geers HC, Bouvy ML, Heerdink ER,. Estimates of statin discontinuation rates are influenced by exposure and outcome definitions. Ann Pharmacother 2011; 45: 576-581
-
(2011)
Ann Pharmacother
, vol.45
, pp. 576-581
-
-
Geers, H.C.1
Bouvy, M.L.2
Heerdink, E.R.3
-
13
-
-
0035800025
-
Postmenopausal hormone use and secondary prevention of coronary events in the nurses' health study a prospective, observational study
-
Grodstein F, Manson JE, Stampfer MJ,. Postmenopausal hormone use and secondary prevention of coronary events in the Nurses' Health Study. A prospective, observational study. Ann Intern Med 2001; 135: 1-8
-
(2001)
Ann Intern Med
, vol.135
, pp. 1-8
-
-
Grodstein, F.1
Manson, J.E.2
Stampfer, M.J.3
-
14
-
-
0035808009
-
Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial
-
Hodis HN, Mack WJ, Lobo RA, Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001; 135: 939-953
-
(2001)
Ann Intern Med
, vol.135
, pp. 939-953
-
-
Hodis, H.N.1
MacK, W.J.2
Lobo, R.A.3
-
15
-
-
32044435429
-
Hormone therapy and coronary heart disease: The role of time since menopause and age at hormone initiation
-
Grodstein F, Manson JE, Stampfer MJ,. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Womens Health 2006; 15: 35-44
-
(2006)
J Womens Health
, vol.15
, pp. 35-44
-
-
Grodstein, F.1
Manson, J.E.2
Stampfer, M.J.3
-
16
-
-
84861409481
-
The timing hypothesis for coronary heart disease prevention with hormone therapy: Past, present and future in perspective
-
Hodis HN, Collins P, Mack WJ, Schierbeck LL,. The timing hypothesis for coronary heart disease prevention with hormone therapy: past, present and future in perspective. Climacteric 2012; 15: 217-228
-
(2012)
Climacteric
, vol.15
, pp. 217-228
-
-
Hodis, H.N.1
Collins, P.2
MacK, W.J.3
Schierbeck, L.L.4
-
17
-
-
61849168916
-
Effects of the selective estrogen receptor modulator raloxifene on coronary outcomes in the raloxifene use for the heart trial: Results of subgroup analyses by age and other factors
-
Collins P, Mosca L, Geiger MJ, Effects of the selective estrogen receptor modulator raloxifene on coronary outcomes in the Raloxifene Use for The Heart trial: results of subgroup analyses by age and other factors. Circulation 2009; 119: 922-930
-
(2009)
Circulation
, vol.119
, pp. 922-930
-
-
Collins, P.1
Mosca, L.2
Geiger, M.J.3
-
18
-
-
24744454395
-
Effects of estrogen replacement therapies on mouse platelet function and glycoprotein vi levels
-
Leng XH, Zhang W, Nieswandt B, Bray PF,. Effects of estrogen replacement therapies on mouse platelet function and glycoprotein VI levels. Circ Res 2005; 97: 415-417
-
(2005)
Circ Res
, vol.97
, pp. 415-417
-
-
Leng, X.H.1
Zhang, W.2
Nieswandt, B.3
Bray, P.F.4
-
19
-
-
18044364454
-
Differential effects of 17β-estradiol, conjugated equine estrogen, and raloxifene on mrna expression, aggregation, and secretion in platelets
-
Jayachandran M, Mukherjee R, Steinkamp T, Differential effects of 17β-estradiol, conjugated equine estrogen, and raloxifene on mRNA expression, aggregation, and secretion in platelets. Am J Physiol Heart Circ Physiol 2005; 288: H2355-H2362
-
(2005)
Am J Physiol Heart Circ Physiol
, vol.288
, pp. H2355-H2362
-
-
Jayachandran, M.1
Mukherjee, R.2
Steinkamp, T.3
-
20
-
-
77955984016
-
Equine estrogens impair nitric oxide production and endothelial nitric oxide synthase transcription in human endothelial cells compared with the natural 17β-estradiol
-
Novensa L, Selent J, Pastor M, Sandberg K, Heras M, Dantas AP,. Equine estrogens impair nitric oxide production and endothelial nitric oxide synthase transcription in human endothelial cells compared with the natural 17β-estradiol. Hypertension 2010; 56: 405-411
-
(2010)
Hypertension
, vol.56
, pp. 405-411
-
-
Novensa, L.1
Selent, J.2
Pastor, M.3
Sandberg, K.4
Heras, M.5
Dantas, A.P.6
-
21
-
-
84868307415
-
Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: Randomised trial
-
Schierbeck LL, Rejnmark L, Tofteng CL, Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ 2012; 345: e6409
-
(2012)
BMJ
, vol.345
, pp. e6409
-
-
Schierbeck, L.L.1
Rejnmark, L.2
Tofteng, C.L.3
-
22
-
-
0037173078
-
Statin therapy, cardiovascular events, and total mortality in the heart and estrogen/progestin replacement study (hers)
-
Herrington DM, Vittinghoff E, Lin F, Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/progestin Replacement Study (HERS). Circulation 2002; 105: 2962-2967
-
(2002)
Circulation
, vol.105
, pp. 2962-2967
-
-
Herrington, D.M.1
Vittinghoff, E.2
Lin, F.3
-
23
-
-
33748965886
-
Role of annexin ii in estrogen-induced macrophage matrix metalloproteinase-9 activity: The modulating effect of statins
-
Hwang J, Hodis HN, Hsiai TK, Asatryan L, Sevanian A,. Role of annexin II in estrogen-induced macrophage matrix metalloproteinase-9 activity: the modulating effect of statins. Atherosclerosis 2006; 189: 76-82
-
(2006)
Atherosclerosis
, vol.189
, pp. 76-82
-
-
Hwang, J.1
Hodis, H.N.2
Hsiai, T.K.3
Asatryan, L.4
Sevanian, A.5
-
24
-
-
0037625637
-
Statins inhibit secretion of metalloproteinases-1,-2,-3, and-9 from vascular smooth muscle cells and macrophages
-
Luan Z, Chase AJ, Newby AC,. Statins inhibit secretion of metalloproteinases-1,-2,-3, and-9 from vascular smooth muscle cells and macrophages. Arterioscler Thromb Vasc Biol 2003; 23: 769-775
-
(2003)
Arterioscler Thromb Vasc Biol
, vol.23
, pp. 769-775
-
-
Luan, Z.1
Chase, A.J.2
Newby, A.C.3
-
25
-
-
23944460333
-
Combined postmenopausal hormone therapy and cardiovascular disease: Toward resolving the discrepancy between observational studies and the women's health initiative clinical trial
-
Prentice RL, Langer R, Stefanick ML, Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial. Am J Epidemiol 2005; 162: 404-414
-
(2005)
Am J Epidemiol
, vol.162
, pp. 404-414
-
-
Prentice, R.L.1
Langer, R.2
Stefanick, M.L.3
-
26
-
-
0345701470
-
Not 15 but 50% of smokers develop COPD? Report from the Obstructive Lung Disease in Northern Sweden Studies
-
Lundback B, Lindberg A, Lindstrom M, Not 15 but 50% of smokers develop COPD? Report from the Obstructive Lung Disease in Northern Sweden Studies. Respir Med 2003; 97: 115-122
-
(2003)
Respir Med
, vol.97
, pp. 115-122
-
-
Lundback, B.1
Lindberg, A.2
Lindstrom, M.3
-
27
-
-
84862897224
-
Venous thrombosis in users of non-oral hormonal contraception: Follow-up study, denmark 2001-10
-
Lidegaard O, Nielsen LH, Skovlund CW, Lokkegaard E,. Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10. BMJ 2012; 344: e2990
-
(2012)
BMJ
, vol.344
, pp. e2990
-
-
Lidegaard, O.1
Nielsen, L.H.2
Skovlund, C.W.3
Lokkegaard, E.4
-
28
-
-
84875193118
-
The impact of medication adherence on coronary artery disease costs and outcomes: A systematic review
-
Bitton A, Choudhry NK, Matlin OS, Swanton K, Shrank WH,. The impact of medication adherence on coronary artery disease costs and outcomes: a systematic review. Am J Med 2013; 126: 357.e7-357.e27
-
(2013)
Am J Med
, vol.126
, pp. 357e7-357e27
-
-
Bitton, A.1
Choudhry, N.K.2
Matlin, O.S.3
Swanton, K.4
Shrank, W.H.5
-
29
-
-
0036370178
-
National health data registers: A nordic heritage to public health
-
Rosen M,. National Health Data Registers: a Nordic heritage to public health. Scand J Public Health 2002; 30: 81-85
-
(2002)
Scand J Public Health
, vol.30
, pp. 81-85
-
-
Rosen, M.1
-
30
-
-
3442889435
-
Interpretation of observational studies
-
Jepsen P, Johnsen SP, Gillman MW, Sorensen HT,. Interpretation of observational studies. Heart 2004; 90: 956-960
-
(2004)
Heart
, vol.90
, pp. 956-960
-
-
Jepsen, P.1
Johnsen, S.P.2
Gillman, M.W.3
Sorensen, H.T.4
-
31
-
-
33845705267
-
Hormone effects on fmri and cognitive measures of encoding: Importance of hormone preparation
-
Gleason CE, Schmitz TW, Hess T, Hormone effects on fMRI and cognitive measures of encoding: importance of hormone preparation. Neurology 2006; 67: 2039-2041
-
(2006)
Neurology
, vol.67
, pp. 2039-2041
-
-
Gleason, C.E.1
Schmitz, T.W.2
Hess, T.3
-
32
-
-
33847116637
-
Hormone therapy and venous thromboembolism among postmenopausal women: Impact of the route of estrogen administration and progestogens: The esther study
-
Canonico M, Oger E, Plu-Bureau G, Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007; 115: 840-845
-
(2007)
Circulation
, vol.115
, pp. 840-845
-
-
Canonico, M.1
Oger, E.2
Plu-Bureau, G.3
|